Discovery of novel dual STAT3/TrxR1 inhibitors via pharmacophore fusion as potent lead compounds for colorectal cancer.
Constitutive activation of STAT3 and dysregulation of the thioredoxin reductase 1 (TrxR1) system are deeply implicated in the pathogenesis, progression, and drug resistance of colorectal cancer (CRC). Herein, guided by a pharmacophore fusion strategy, we rationally designed and synthesized a novel series of STAT3/TrxR1...